This online educational activity has been planned in accordance with the AASLD Financial Disclosure Policy and ACCME Standards for the Integrity and Independence for Accredited Continuing Education by members of the AASLD Transplant Hepatology Board Review Course faculty, the AASLD Maintenance of Certification Committee and the AASLD Governing Board. As an accredited provider, AASLD must collect information from all planners, faculty and others in the planning and control of continuing medical education (CME) activities to disclose all of their financial relationships with ineligible companies within the prior 24 months. Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. There is no minimum financial threshold; individuals must disclose all financial relationships, regardless of the amount, in ineligible companies. Individuals must disclose financial relationships with ineligible companies regardless of their view of the relevance of the relationship to the education.
The American Association for the Study of Liver Diseases (AASLD) has implemented a system to resolve conflicts of interest for each CME activity to help ensure content is objective, fair balanced, independent, and free of commercial bias. Conflicts, if any, are resolved through one or more processes. All relevant conflicts pertaining to this activity have been mitigated.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Jacki Chen, PhD
Consulting: GlaxoSmithKline, Gilead Sciences, Arbutus Biopharma
Patient Advisory Board: Hepatitis B Foundation, Taiwan Hepatitis Information & Care Association, AASLD
Jordan J. Feld, MD, MPH, FAASLD
Consulting: Precision Biosciences, Vir, Roche, GlaxoSmithKline, Gilead, Bluejay Therapeutics, AbbVie, Aligos, Therapeutics, Gilead
Marc G. Ghany, MD, MHSc, FAASLD
Nothing to disclose
Arthur Kim, MD
Consulting: Clinical Care Options;
Data Safety Monitoring Board: Kintor, Shionogi Inc.
Joseph Lim, MD, FAASLD
Nothing to disclose
Anna Lok, MD, FAASLD
Data Safety Monitoring Board: Novo Nordisk
Scientific Consultant/Advisor: Abbott, Brii Biosciences, Chroma, Enochian, GlaxoSmithKline, Grifols, Moderna, Precision, Pfizer, Roche, TARGET, Virion, Zenasbio
Khaled S. Mohammed, MD
Nothing to disclose
M. Hussan Murad, MD, MPH
Nothing to disclose
Susanna Naggie, MD
Consulting: Pardes
Stock Options: Vir Bio, managed by an independent company as allowed by AASLD COI policy.
Mindie H. Nguyen, MD, MAS, AGAF, FAASLD:
Honorarium: CLDF
Calvin Q. Pan, MD, MACP, FAASLD
Consulting: Gilead
Amy Tang, MD
Nothing to disclose
Norah Terrault, MD, MPH, FAASLD
Nothing to disclose
Norberto Rodriguez-Baez
Nothing to disclose
Mark S. Sulkowski, MD, FAASLD
Scientific Consultant: Gilead, Precision Biosciences, Aligos, AbbVie, Virion, Antios, GK
Data Safety Monitoring Board: Gilead
Su H. Wang, MD, MPH, FACP
Nothing to disclose